- recruitingTherapeutic exploratory (Phase II)
A phase 2 study of trifluridine/tipiracil in patients with ER-positive, HER2-negative advanced breast cancer that previously received chemotherapy (BOOG 2019-01 TIBET study)
This study looks at a new treatment called Lonsurf for women with advanced breast cancer that's grown despite other treatments. We want to see how many patients' cancer stops growing or shrinks after 8 weeks on Lonsurf.
Netherlands - active not recruitingPHASE3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
This study compares a new medicine called palazestrant with standard treatments for advanced breast cancer that has grown despite previous hormone therapy. It's for men and women whose cancer is ER-positive and HER2-negative.
United States · Argentina · Australia - active not recruitingPHASE3
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
This study is testing a new medicine, ARV-471, against an existing treatment, fulvestrant, for advanced breast cancer that has spread. It's for people who have already had certain hormone therapies. The aim is to see if ARV-471 is safe and effective.
United States · Argentina · Australia - recruitingPHASE3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.
United States · Argentina · Australia - active not recruitingPHASE2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
This study looks at a new combination of experimental drugs, disitamab vedotin and tucatinib, for advanced breast or stomach cancers that have a specific marker called HER2. It aims to see how safe and effective this treatment is, and what side effects it might cause.
United States · Australia · Canada - recruitingPHASE4
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
This study looks at how well a breast cancer drug called ribociclib works for women with a specific type of advanced breast cancer and why it might or might not work. It also checks for side effects and how patients feel.
Germany - recruitingPHASE2
Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
This study aims to understand why some cancer treatments, called ADCs, stop working. By looking at samples from patients with advanced breast, stomach, bladder, or lung cancer, researchers hope to find better ways to choose the right ADC for each person and reduce side effects.
France - recruitingPHASE3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
This study compares two drug combinations, RLY-2608 with fulvestrant, and capivasertib with fulvestrant, for advanced breast cancer that has a specific gene change (PIK3CA mutation) and has grown after previous treatment. It's for HR+/HER2- breast cancer.
United States · Argentina · Australia - recruitingPHASE3
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
This study is testing a new drug, capivasertib, for advanced breast cancer that's grown despite previous treatment. It aims to see how well it works and if it improves quality of life for patients.
Belgium · Germany · Portugal - active not recruitingPHASE1, PHASE2
Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
This study is testing a new combination of two drugs, Debio0123 and Sacituzumab govitecan, for people with advanced triple-negative breast cancer (TNBC) or hormone-receptor-positive/HER2-negative (HR+/HER2-) breast cancer. It aims to see if this treatment is safe and effective.
Spain · United Kingdom - recruitingPHASE2
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
This study looks at a new drug, trastuzumab deruxtecan (T-DXd), for advanced breast cancer that has specific features. It compares this drug to standard treatments to see if it helps patients live longer without their cancer getting worse.
Austria · Belgium · France - recruitingPHASE2
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
This study is looking at a new combination of two drugs, Camizestrant and Atirmociclib, for women with advanced breast cancer. It focuses on those whose cancer has grown despite previous treatment with a specific type of drug (CDK4/6 inhibitor). The main goals are to check if the combination is safe and if it helps fight the cancer.
United States · United Kingdom - active not recruitingPHASE2
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
This study looks at adding a new drug, ipatasertib, to standard treatment for advanced breast cancer that hasn't responded well to initial therapy. It uses a blood test to identify patients who might benefit most from this additional treatment.
United Kingdom - recruitingPHASE3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
This study is for people with advanced ER+/HER2- breast cancer with an ESR1 gene change, whose cancer has grown despite previous treatments. It tests a new drug called elacestrant alongside an existing one, everolimus, to see if this combination works better at stopping the cancer from growing.
Austria · Brazil · Czechia